Le diagnostic repose sur l'examen clinique, l'imagerie et la culture fongique.
MucormycoseDiagnostic médical
#2
Quels tests sont utilisés pour confirmer la mucormycose ?
Les tests incluent des biopsies, des cultures et des examens d'imagerie comme l'IRM.
BiopsieImagerie par résonance magnétique
#3
Quels signes cliniques indiquent une mucormycose ?
Les signes incluent des douleurs faciales, des écoulements nasaux et des lésions cutanées.
SymptômesMucormycose
#4
La mucormycose peut-elle être confondue avec d'autres infections ?
Oui, elle peut être confondue avec d'autres mycoses ou infections bactériennes.
Infections fongiquesDiagnostic différentiel
#5
Quel rôle joue l'imagerie dans le diagnostic ?
L'imagerie aide à visualiser l'étendue de l'infection et à guider le traitement.
Imagerie médicaleMucormycose
Symptômes
5
#1
Quels sont les symptômes courants de la mucormycose ?
Les symptômes incluent fièvre, douleur faciale, congestion nasale et vision floue.
SymptômesMucormycose
#2
La mucormycose affecte-t-elle les poumons ?
Oui, elle peut provoquer des symptômes respiratoires comme la toux et la dyspnée.
MucormycoseSymptômes respiratoires
#3
Quels symptômes cutanés peuvent apparaître ?
Des lésions cutanées, des ulcères et des nécroses peuvent se développer.
Lésions cutanéesMucormycose
#4
Y a-t-il des symptômes neurologiques associés ?
Oui, des maux de tête, des troubles de la conscience et des convulsions peuvent survenir.
Symptômes neurologiquesMucormycose
#5
Comment évoluent les symptômes de la mucormycose ?
Les symptômes peuvent s'aggraver rapidement, nécessitant une intervention urgente.
Évolution des symptômesMucormycose
Prévention
5
#1
Comment prévenir la mucormycose ?
La prévention inclut le contrôle des facteurs de risque et une bonne hygiène.
PréventionMucormycose
#2
Les patients diabétiques doivent-ils être vigilants ?
Oui, un contrôle strict de la glycémie est crucial pour prévenir la mucormycose.
DiabèteMucormycose
#3
Les personnes immunodéprimées doivent-elles éviter certains environnements ?
Oui, éviter les environnements humides et les zones de champignons est recommandé.
ImmunodépressionPrévention
#4
Les masques peuvent-ils aider à prévenir l'infection ?
Les masques peuvent réduire l'exposition aux spores fongiques dans certains environnements.
MasquesPrévention
#5
Y a-t-il des vaccins contre la mucormycose ?
Actuellement, il n'existe pas de vaccin spécifique contre la mucormycose.
VaccinsMucormycose
Traitements
5
#1
Quel est le traitement principal de la mucormycose ?
Le traitement principal est l'administration d'antifongiques comme l'amphotéricine B.
AntifongiquesMucormycose
#2
La chirurgie est-elle nécessaire dans le traitement ?
Oui, la débridement chirurgical peut être nécessaire pour enlever les tissus nécrosés.
ChirurgieMucormycose
#3
Combien de temps dure le traitement antifongique ?
Le traitement peut durer plusieurs semaines, selon la gravité de l'infection.
Durée du traitementMucormycose
#4
Quels sont les effets secondaires des antifongiques ?
Les effets secondaires peuvent inclure des troubles rénaux et des réactions allergiques.
Effets secondairesAntifongiques
#5
Peut-on utiliser des traitements alternatifs ?
Les traitements alternatifs ne sont pas recommandés sans avis médical, car ils peuvent être inefficaces.
Traitements alternatifsMucormycose
Complications
5
#1
Quelles sont les complications possibles de la mucormycose ?
Les complications incluent la perte de vision, des infections systémiques et la mort.
ComplicationsMucormycose
#2
La mucormycose peut-elle entraîner des infections cérébrales ?
Oui, elle peut provoquer des infections cérébrales graves comme la rhinocéphalite.
Infections cérébralesMucormycose
#3
Quels sont les risques de récidive ?
Les patients immunodéprimés ont un risque élevé de récidive après traitement.
RécidiveMucormycose
#4
Comment la mucormycose affecte-t-elle la qualité de vie ?
Elle peut gravement affecter la qualité de vie en raison des séquelles physiques et psychologiques.
Qualité de vieMucormycose
#5
Les complications sont-elles fréquentes ?
Les complications sont fréquentes chez les patients à haut risque, surtout sans traitement rapide.
ComplicationsMucormycose
Facteurs de risque
5
#1
Qui est le plus à risque de mucormycose ?
Les personnes immunodéprimées, diabétiques ou ayant subi une transplantation sont à risque.
Facteurs de risqueMucormycose
#2
Le diabète mal contrôlé augmente-t-il le risque ?
Oui, un diabète mal contrôlé est un facteur de risque majeur pour la mucormycose.
DiabèteMucormycose
#3
Les traitements immunosuppresseurs sont-ils un facteur de risque ?
Oui, les traitements immunosuppresseurs augmentent le risque d'infections fongiques comme la mucormycose.
ImmunosuppresseursMucormycose
#4
Les brûlures ou traumatismes cutanés augmentent-ils le risque ?
Oui, les blessures cutanées peuvent servir de porte d'entrée pour l'infection fongique.
Traumatismes cutanésMucormycose
#5
L'utilisation prolongée de corticostéroïdes est-elle risquée ?
Oui, l'utilisation prolongée de corticostéroïdes peut affaiblir le système immunitaire et augmenter le risque.
CorticostéroïdesMucormycose
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Mucormycose : Questions médicales les plus fréquentes",
"headline": "Mucormycose : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Mucormycose : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-13",
"dateModified": "2025-02-07",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Mucormycose"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Zygomycose",
"url": "https://questionsmedicales.fr/mesh/D020096",
"about": {
"@type": "MedicalCondition",
"name": "Zygomycose",
"code": {
"@type": "MedicalCode",
"code": "D020096",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.150.703.980"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Mucormycose",
"alternateName": "Mucormycosis",
"code": {
"@type": "MedicalCode",
"code": "D009091",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "S Sharma",
"url": "https://questionsmedicales.fr/author/S%20Sharma",
"affiliation": {
"@type": "Organization",
"name": "Medical Education Department, Jaipur, India."
}
},
{
"@type": "Person",
"name": "Hariprasath Prakash",
"url": "https://questionsmedicales.fr/author/Hariprasath%20Prakash",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. harisath2003@gmail.com."
}
},
{
"@type": "Person",
"name": "Arunaloke Chakrabarti",
"url": "https://questionsmedicales.fr/author/Arunaloke%20Chakrabarti",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. arunaloke@hotmail.com."
}
},
{
"@type": "Person",
"name": "Ilse D Jacobsen",
"url": "https://questionsmedicales.fr/author/Ilse%20D%20Jacobsen",
"affiliation": {
"@type": "Organization",
"name": "Research Group Microbial Immunology, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute (HKI), Jena, Germany. ilse.jacobsen@leibniz-hki.de."
}
},
{
"@type": "Person",
"name": "François Danion",
"url": "https://questionsmedicales.fr/author/Fran%C3%A7ois%20Danion",
"affiliation": {
"@type": "Organization",
"name": "Université Paris Descartes, Centre d'Infectiologie Necker Pasteur, IHU Imagine, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 75015 Paris, France. francois.danion@aphp.fr."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Effect of Instrumented Spine Surgery on Length of Stay.",
"datePublished": "2023-05-15",
"url": "https://questionsmedicales.fr/article/37186578",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5435/JAAOSGlobal-D-22-00231"
}
},
{
"@type": "ScholarlyArticle",
"name": "Perioperative risk factors impact on intensive care unit length of stay (ICU length of stay) in oral squamous cell carcinoma.",
"datePublished": "2023-09-01",
"url": "https://questionsmedicales.fr/article/37658335",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12903-023-03304-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Frailty, length of stay and cost in hip fracture patients.",
"datePublished": "2022-10-05",
"url": "https://questionsmedicales.fr/article/36197493",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00198-022-06553-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Length of Stay in Patients Undergoing Tracheoplasty: A NSQIP Study.",
"datePublished": "2022-10-10",
"url": "https://questionsmedicales.fr/article/36214517",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/lary.30424"
}
},
{
"@type": "ScholarlyArticle",
"name": "Genetic Testing and Hospital Length of Stay in Neonates With Epilepsy.",
"datePublished": "2022-06-02",
"url": "https://questionsmedicales.fr/article/35751960",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pediatrneurol.2022.05.011"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Infection",
"item": "https://questionsmedicales.fr/mesh/D007239"
},
{
"@type": "ListItem",
"position": 3,
"name": "Infections bactériennes et mycoses",
"item": "https://questionsmedicales.fr/mesh/D001423"
},
{
"@type": "ListItem",
"position": 4,
"name": "Mycoses",
"item": "https://questionsmedicales.fr/mesh/D009181"
},
{
"@type": "ListItem",
"position": 5,
"name": "Zygomycose",
"item": "https://questionsmedicales.fr/mesh/D020096"
},
{
"@type": "ListItem",
"position": 6,
"name": "Mucormycose",
"item": "https://questionsmedicales.fr/mesh/D009091"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Mucormycose - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Mucormycose",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Mucormycose",
"description": "Comment diagnostique-t-on la mucormycose ?\nQuels tests sont utilisés pour confirmer la mucormycose ?\nQuels signes cliniques indiquent une mucormycose ?\nLa mucormycose peut-elle être confondue avec d'autres infections ?\nQuel rôle joue l'imagerie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D009091?mesh_terms=Length+of+Stay#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Mucormycose",
"description": "Quels sont les symptômes courants de la mucormycose ?\nLa mucormycose affecte-t-elle les poumons ?\nQuels symptômes cutanés peuvent apparaître ?\nY a-t-il des symptômes neurologiques associés ?\nComment évoluent les symptômes de la mucormycose ?",
"url": "https://questionsmedicales.fr/mesh/D009091?mesh_terms=Length+of+Stay#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Mucormycose",
"description": "Comment prévenir la mucormycose ?\nLes patients diabétiques doivent-ils être vigilants ?\nLes personnes immunodéprimées doivent-elles éviter certains environnements ?\nLes masques peuvent-ils aider à prévenir l'infection ?\nY a-t-il des vaccins contre la mucormycose ?",
"url": "https://questionsmedicales.fr/mesh/D009091?mesh_terms=Length+of+Stay#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Mucormycose",
"description": "Quel est le traitement principal de la mucormycose ?\nLa chirurgie est-elle nécessaire dans le traitement ?\nCombien de temps dure le traitement antifongique ?\nQuels sont les effets secondaires des antifongiques ?\nPeut-on utiliser des traitements alternatifs ?",
"url": "https://questionsmedicales.fr/mesh/D009091?mesh_terms=Length+of+Stay#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Mucormycose",
"description": "Quelles sont les complications possibles de la mucormycose ?\nLa mucormycose peut-elle entraîner des infections cérébrales ?\nQuels sont les risques de récidive ?\nComment la mucormycose affecte-t-elle la qualité de vie ?\nLes complications sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D009091?mesh_terms=Length+of+Stay#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Mucormycose",
"description": "Qui est le plus à risque de mucormycose ?\nLe diabète mal contrôlé augmente-t-il le risque ?\nLes traitements immunosuppresseurs sont-ils un facteur de risque ?\nLes brûlures ou traumatismes cutanés augmentent-ils le risque ?\nL'utilisation prolongée de corticostéroïdes est-elle risquée ?",
"url": "https://questionsmedicales.fr/mesh/D009091?mesh_terms=Length+of+Stay#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on la mucormycose ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique, l'imagerie et la culture fongique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer la mucormycose ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent des biopsies, des cultures et des examens d'imagerie comme l'IRM."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une mucormycose ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des douleurs faciales, des écoulements nasaux et des lésions cutanées."
}
},
{
"@type": "Question",
"name": "La mucormycose peut-elle être confondue avec d'autres infections ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres mycoses ou infections bactériennes."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'imagerie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie aide à visualiser l'étendue de l'infection et à guider le traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de la mucormycose ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fièvre, douleur faciale, congestion nasale et vision floue."
}
},
{
"@type": "Question",
"name": "La mucormycose affecte-t-elle les poumons ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut provoquer des symptômes respiratoires comme la toux et la dyspnée."
}
},
{
"@type": "Question",
"name": "Quels symptômes cutanés peuvent apparaître ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des lésions cutanées, des ulcères et des nécroses peuvent se développer."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maux de tête, des troubles de la conscience et des convulsions peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment évoluent les symptômes de la mucormycose ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver rapidement, nécessitant une intervention urgente."
}
},
{
"@type": "Question",
"name": "Comment prévenir la mucormycose ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut le contrôle des facteurs de risque et une bonne hygiène."
}
},
{
"@type": "Question",
"name": "Les patients diabétiques doivent-ils être vigilants ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un contrôle strict de la glycémie est crucial pour prévenir la mucormycose."
}
},
{
"@type": "Question",
"name": "Les personnes immunodéprimées doivent-elles éviter certains environnements ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter les environnements humides et les zones de champignons est recommandé."
}
},
{
"@type": "Question",
"name": "Les masques peuvent-ils aider à prévenir l'infection ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les masques peuvent réduire l'exposition aux spores fongiques dans certains environnements."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins contre la mucormycose ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccin spécifique contre la mucormycose."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal de la mucormycose ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est l'administration d'antifongiques comme l'amphotéricine B."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle nécessaire dans le traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la débridement chirurgical peut être nécessaire pour enlever les tissus nécrosés."
}
},
{
"@type": "Question",
"name": "Combien de temps dure le traitement antifongique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut durer plusieurs semaines, selon la gravité de l'infection."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des antifongiques ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des troubles rénaux et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des traitements alternatifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements alternatifs ne sont pas recommandés sans avis médical, car ils peuvent être inefficaces."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la mucormycose ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la perte de vision, des infections systémiques et la mort."
}
},
{
"@type": "Question",
"name": "La mucormycose peut-elle entraîner des infections cérébrales ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut provoquer des infections cérébrales graves comme la rhinocéphalite."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de récidive ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients immunodéprimés ont un risque élevé de récidive après traitement."
}
},
{
"@type": "Question",
"name": "Comment la mucormycose affecte-t-elle la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut gravement affecter la qualité de vie en raison des séquelles physiques et psychologiques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont fréquentes chez les patients à haut risque, surtout sans traitement rapide."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque de mucormycose ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes immunodéprimées, diabétiques ou ayant subi une transplantation sont à risque."
}
},
{
"@type": "Question",
"name": "Le diabète mal contrôlé augmente-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un diabète mal contrôlé est un facteur de risque majeur pour la mucormycose."
}
},
{
"@type": "Question",
"name": "Les traitements immunosuppresseurs sont-ils un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements immunosuppresseurs augmentent le risque d'infections fongiques comme la mucormycose."
}
},
{
"@type": "Question",
"name": "Les brûlures ou traumatismes cutanés augmentent-ils le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les blessures cutanées peuvent servir de porte d'entrée pour l'infection fongique."
}
},
{
"@type": "Question",
"name": "L'utilisation prolongée de corticostéroïdes est-elle risquée ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'utilisation prolongée de corticostéroïdes peut affaiblir le système immunitaire et augmenter le risque."
}
}
]
}
]
}
Research Group Microbial Immunology, Leibniz Institute for Natural Product Research and Infection Biology-Hans Knöll Institute (HKI), Jena, Germany. ilse.jacobsen@leibniz-hki.de.
Institute of Microbiology, Faculty of Biological Sciences, Friedrich Schiller University Jena, Jena, Germany. ilse.jacobsen@leibniz-hki.de.
Université Paris Descartes, Centre d'Infectiologie Necker Pasteur, IHU Imagine, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 75015 Paris, France. francois.danion@aphp.fr.
Université Paris Descartes, Centre d'Infectiologie Necker Pasteur, IHU Imagine, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), 75015 Paris, France. fanny.lanternier@aphp.fr.
Centre National de Référence mycoses invasives et antifongiques, Unité de Mycologie Moléculaire, Institut Pasteur, 75015 Paris, France. fanny.lanternier@aphp.fr.
Service of Infectious Diseases, Department of Medicine, Lausanne University Hospital, University of Lausanne, Rue du Bugnon 48, 1011 Lausanne, Switzerland.
Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital, University of Lausanne, Rue du Bugnon 48, 1011 Lausanne, Switzerland.
Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.
Division of Infectious Diseases, Department of Internal Medicine, Duke University Medical Center, Hanes House, Duke University Medical Center, 315 Trent Drive, Durham, NC 27710, USA.
Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Health System, F4005 UH-South- SPC 5226, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA. Electronic address: mmiceli@med.umich.edu.
Total joint arthroplasty studies have identified that surgeries that take place later in the week have a longer length of stay compared with those earlier in the week. This has not been demonstrated i...
All instrumented spine surgeries in 2019 at a single academic tertiary center were retrospectively reviewed. Patients were categorized for surgical day and discharge disposition to home or a rehabilit...
Seven hundred six patients were included in the analysis. Excluding Saturday, there were no differences in length of stay based on the day of surgery. Age older than 75 years, female, American Society...
Day of surgery does not affect length of stay in instrumented spine surgeries. Discharge to a rehabilitation facility, however, did increase the length of stay as did age older than 75 years, higher A...
The trend in postoperative care for free flap patients is to deescalate from routine ICU admission into a specialty recovery unit. This study aims to investigate the predictive parameters in a routine...
All patients who underwent ablative surgery for OSCC with free flap reconstruction and were managed in the ICU were included in this study. The primary outcome was ICU-length of stay. Perioperative, o...
The study included 136 homogeneous patients, with a mean ICU length of stay of 4.5 (± 4.43 day). Patients with pre-operative positive renal dysfunction (P = 0.004), peripheral vascular disease (P < 0....
Patients with perioperative severe renal dysfunction, peripheral vascular disease, postoperative complication or high NYHA class are prone to have a significantly longer ICU length of stay. Several fa...
A hip fracture causes high morbidity and mortality. Frailty is associated with adverse outcomes and increased costs. Frailty measured using the Hospital Frailty Risk Score (HFRS) is associated with hi...
Hip fractures account for an increasing number of hospital admissions around the world and are associated with high rates of morbidity and mortality. Frailty is increasingly recognized to be associate...
A retrospective analysis was performed on 1014 patients ≥ 60 years who presented with a hip fracture between January 2016 to June 2020. Each patient was classified into HFRS low, intermediate or high ...
Median total hospitalization costs were significantly higher in the highest HFRS (SGD$22,432) patients as compared to intermediate (SGD$18,759) and low HFRS (SGD$15,671) patients. The difference betwe...
Frailty is associated with a marked increase in total costs in hip fracture patients. HFRS proved useful in estimating LOS and outcomes for older patients with hip fractures....
Prolonged length of stay (LOS) has been associated with increased morbidity and resource utilization in various surgical procedures. We aim to determine factors associated with increased hospital stay...
The 2012-2018 National Surgical Quality Improvement Program (NSQIP) database was queried for patients undergoing tracheoplasty. Patient LOS was the primary clinical outcome. A LOS >75th percentile was...
A total of 252 patients were queried. The majority of patients were female (67.5%), white (82.4%), and over the age of 65 (77.0%). Patients had a median LOS of 7 days with the 75th percentile cutoff b...
This study elucidates factors associated with prolonged LOS in patients undergoing tracheoplasty. Patients with COPD and chronic steroid use were significantly associated with prolonged LOS....
4 Laryngoscope, 133:1938-1942, 2023....
We evaluated changes in genetic testing for neonatal-onset epilepsy and associated short-term outcomes over an 8-year period among a cohort of patients in the neonatal intensive care unit (NICU) at a ...
Our primary outcome was a change in length of stay (LOS) after 2018. We also ascertained severity of illness with the Neonatal Sequential Organ Failure Assessment (nSOFA), type and result of genetic t...
Fifty-three infants with genetic testing were included; 20 infants were tested after 2018. A total of 4160 infants in the NICU without genetic testing were used as reference. In the genetic testing gr...
In this cohort, changes in genetic testing for neonatal-onset epilepsy were associated with shorter LOS that was not explained by changes in severity of illness, birth weight, or the average LOS in th...
There are several factors that influence the length of hospital stay (LoHS) in patients with community-acquired pneumonia (CAP). There is currently no study in the literature that correlates laborator...
To find the association of laboratory parameters with the LoHS in patients with community-acquired pneumonia....
An observational, prospective, longitudinal, and controlled study was conducted in the emergency room of a secondary level hospital....
The mean time of LoHS in patients with CAP was 6.6 ± 3.0 days. The parameters of laboratory of monocytes, basophils and segmented neutrophils presented a correlation (Spearman rho) of 0.363, 0.364 and...
LoHS in patients with CAP is related to the counting of monocytes, basophils, and neutrophils at the time of the hospital admittance and it was increased in patients with SAH and patients with COPD....
Emergency general surgery patients undergoing laparoscopic surgery are at reduced risk of mortality and may require reduced length of critical care stay. This study investigated the effect of laparosc...
Data were retrieved for all patients entered into the NELA database between 2013 and 2018. Only high-risk surgical patients (P-POSSUM predicted mortality risk of ≥ 5%) were included. Patients undergoi...
A total of 66,517 high-risk patients received emergency major abdominal surgery. A laparoscopic procedure was attempted in 6998 (10.5%); of these, the procedure was competed laparoscopically in 3492 (...
The results of this study suggest that in patients at high risk of post-operative mortality, laparoscopic emergency bowel surgery leads to a reduced length of critical care stay, overall length of sta...
The Center for Medicaid and Medicare Services predicts the length of stay for pediatric burn patients based on several variables. However, many patients exceed their anticipated length. This study loo...
We conducted a retrospective chart review of 535 pediatric burn patients admitted to our academic hospital from January 2018 to December 2020. 405 patients met inclusion criteria. Data were collected ...
Average patient age was 3.36 years. 72.3% were treated for scald burns. Average length of stay was 13.5 days. 20.5% (n = 83) of patients exceeded their predicted length of stay. In comparing patients ...
Twenty percent of pediatric burn patients had a longer length of stay than predicted by the Center for Medicaid and Medicare Services. Many factors were strongly associated with a longer-than-predicte...
Length of stay (LOS) and readmissions are common measures to evaluate quality of health care. The objective of this study was to evaluate factors related to hospital LOS and readmission within 90 days...
Using a single institution database, patients who underwent CEA for carotid stenosis between 2014 and 2019 were identified. Asymptomatic carotid stenosis (no history of any stroke or transient ischemi...
There were 125 patients identified who underwent CEA for 133 carotid stenosis, and 8 patients had bilateral CEA; of which 36.8% were asymptomatic carotid stenosis with the remaining being operated on ...
More than half of patients undergoing CEA for carotid stenosis were discharged after postoperative day 1. Interventions on modifiable clinical risk factors, such as morning CEA scheduling and manageme...
Extended venous thromboembolism prophylaxis (eVTEp) is recommended for select patients who have undergone major abdominopelvic surgery to prevent postdischarge venous thromboembolism (pdVTE). Criteria...
A retrospective cohort study of patients undergoing abdominopelvic surgery from January 2016 to February 2020 was performed using data from the Michigan Surgical Quality Collaborative. pdVTE was the m...
A total of 45,637 patients underwent abdominopelvic surgery. Of which, 3063 (6.71%) were prescribed eVTEp. Two hundred eighty-five (0.62%) had pdVTE. Of the 285, 59 (21%) patients received eVTEp, whil...
pdVTE was associated with increasing LOS but not with other VTE risk factors after propensity score matching. Current guidelines for eVTEp do not include LOS. Our findings suggest that LOS >5 d should...
